Gilead needs to stop wait­ing and start buy­ing; Let's em­brace Chi­na as a new bio­phar­ma pow­er

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.